Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 7;22(11):6148.
doi: 10.3390/ijms22116148.

A New Ultrasensitive Bioluminescence-Based Method for Assaying Monoacylglycerol Lipase

Affiliations

A New Ultrasensitive Bioluminescence-Based Method for Assaying Monoacylglycerol Lipase

Matteo Miceli et al. Int J Mol Sci. .

Abstract

A novel bioluminescent Monoacylglycerol lipase (MAGL) substrate 6-O-arachidonoylluciferin, a D-luciferin derivative, was synthesized, physico-chemically characterized, and used as highly sensitive substrate for MAGL in an assay developed for this purpose. We present here a new method based on the enzymatic cleavage of arachidonic acid with luciferin release using human Monoacylglycerol lipase (hMAGL) followed by its reaction with a chimeric luciferase, PLG2, to produce bioluminescence. Enzymatic cleavage of the new substrate by MAGL was demonstrated, and kinetic constants Km and Vmax were determined. 6-O-arachidonoylluciferin has proved to be a highly sensitive substrate for MAGL. The bioluminescence assay (LOD 90 pM, LOQ 300 pM) is much more sensitive and should suffer fewer biological interferences in cells lysate applications than typical fluorometric methods. The assay was validated for the identification and characterization of MAGL modulators using the well-known MAGL inhibitor JZL184. The use of PLG2 displaying distinct bioluminescence color and kinetics may offer a highly desirable opportunity to extend the range of applications to cell-based assays.

Keywords: PLG2; bioluminescence; kinetic assay; monoacylglycerol lipase.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Scheme 1
Scheme 1
Bioluminescence reactions of compound 6′-O-arachidonoylluciferin (ArLuc-1). The substrate chemical structure and biochemical reactions leading to 562 nm peak light emission (λ max) are shown.
Scheme 2
Scheme 2
Chemical synthesis of ArLuc-1.
Figure 1
Figure 1
Comparison of luminescence produced by ArLuc-1 in presence (●) or absence (▪) of Monoacylglycerol lipase (MAGL). Data represent mean ± standard deviation (SD).
Figure 2
Figure 2
PLG2 luminescence emission in the presence of varying concentrations from 0.5 to 5% of DMSO. Error bars represent mean ± SD.
Figure 3
Figure 3
Luminescence (RLU) of PLG2 as a linear function of LH2 concentration in the presence of 2.5% DMSO. All points are expressed as mean ± SD.
Figure 4
Figure 4
PLG2 activity in presence of the indicated concentrations of ArLuc-1. Error bars represent mean ± SD.
Figure 5
Figure 5
Kinetic study of MAGL activity with ArLuc-1. Data are reported as mean ± SD. The curve model is that of the Michaelis–Menten.
Figure 6
Figure 6
Concentration-dependent inhibition of JZL184 on MAGL. Data, reported as mean ± SD, are expressed as the percentage of controls (without JZL184).
Figure 7
Figure 7
Top scoring docking pose of compound ArLuc-1 (green stick) into the MAGL binding site. Residues are numbered according to the PDB crystal (5ZUN) convention. The triad catalytic residues are shown in orange sticks, those forming the oxyanion hole in magenta sticks. H-bonds and the π–π stacking interaction are represented with yellow and blue dashed lines, respectively. The black arrow represents the distance between the oxygen atom of the hydroxyl group of Ser122 and the carbon of the carbonyl group of ArLuc-1.
Figure 8
Figure 8
2D representation of interactions between MAGL binding site and ArLuc-1.

Similar articles

Cited by

References

    1. Joshi N., Onaivi E.S. Endocannabinoid System Components: Overview and Tissue Distribution. Adv. Exp. Med. Biol. 2019;1162:1–12. doi: 10.1007/978-3-030-21737-2_1. - DOI - PubMed
    1. Meccariello R. Endocannabinoid System in Health and Disease: Current Situation and Future Perspectives. Int. J. Mol. Sci. 2019;1162:3549. doi: 10.3390/ijms21103549. - DOI - PMC - PubMed
    1. Freitas H.R., Isaac A.R., Malcher-Lopes R., Diaz B.L., Trevenzoli I.H., de Melo Reis R.A. Polyunsaturated fatty acids and endocannabinoids in health and disease. Nutr. Neurosci. 2018;21:695–714. doi: 10.1080/1028415X.2017.1347373. - DOI - PubMed
    1. Ottria R., Cappelletti L., Ravelli A., Mariotti M., Gigli F., Romagnoli S., Ciuffreda P., Banfi G., Drago L. Plasma endocannabinoid behaviour in total knee and hip arthroplasty. J. Biol. Regul. Homeost. Agents. 2016;30:1147–1152. - PubMed
    1. Pezzilli R., Ciuffreda P., Ottria R., Ravelli A., Melzi d’Eril G., Barassi A. Serum endocannabinoids in assessing pain in patients with chronic pancreatitis and in those with pancreatic ductal adenocarcinoma. Scand. J. Gastroenterol. 2017;52:1133–1139. doi: 10.1080/00365521.2017.1342139. - DOI - PubMed

MeSH terms

LinkOut - more resources